The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
D000818:Animals; D003913:Dextroamphetamine / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use; D007099:Imipramine / Q000627:therapeutic use; D007490:Iproniazid / Q000627:therapeutic use; D007520:Isocarboxazid / Q000627:therapeutic use; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009526:Nialamide / Q000627:therapeutic use; D009538:Nicotine; D009662:Nortropanes / Q000494:pharmacology; D010293:Pargyline / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010546:Perphenazine; D010624:Phenelzine / Q000627:therapeutic use; D010830:Physostigmine; D051381:Rats; D012601:Scopolamine / Q000627:therapeutic use; D013451:Sulfonic Acids / Q000627:therapeutic use; D014043:Tolazoline / Q000627:therapeutic use; D014202:Tremor / Q000139:chemically induced; D014203:Tremorine; D014282:Trihexyphenidyl / Q000627:therapeutic use; D014363:Tryptamines / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D009662:Nortropanes; D013451:Sulfonic Acids; D014363:Tryptamines; D007520:Isocarboxazid; D009538:Nicotine; D014282:Trihexyphenidyl; D004155:Diphenhydramine; D010293:Pargyline; D010830:Physostigmine; D014043:Tolazoline; D007490:Iproniazid; D012601:Scopolamine; D010546:Perphenazine; D010624:Phenelzine; D007099:Imipramine; D009526:Nialamide; D003913:Dextroamphetamine; D014203:Tremorine